NEW YORK, May 28 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an internationalbiopharmaceutical company with operations in the U.S. and China, announced that the Company's Director of Clinical Affairs and Apheresis, Lee Clough, BSN, RN, HP (ASCP), has been selected
ASFA is an organization of physicians, scientists, and allied health professionals whose mission is to lead the field of apheresis through patient and donor care, research, education, and advocacy. Ms. Clough's presentation, entitled "Leaders Developing Leaders", will define the leadership role and discuss how to identify and train effective leaders to successfully manage the practice of apheresis medicine. Based on her experience at NeoStem and prior work at Children's National Medical Center as the Manager of the Blood Donor Center and Therapeutic Apheresis, Ms. Clough will discuss how to effectively combine the necessary technical skills and critical leadership skills to successfully manage internal and external relationships in apheresis medicine.
"As a pioneer in the field of autologous adult stem cell collection, our collection centers have been using the minimally invasive apheresis technique to extract stem cells from the body. We are proud to share our experience and knowledge in the area to help advance the apheresis field," said Robin Smith, M.D., NeoStem's CEO and Chairman of the board of directors. "NeoStem remains committed to expanding its adult stem cell collection network to help healthy individuals collect and store their cells for future use and is on track to have 10 stem cell collection centers in the U.S. by the end of the year."
NeoStem's minimally invasive adult stem collection procedure uses the mobilization process to increase the number of stem cells in the blood circulation. Then through apheresis, a painless and safe procedure, the stem cells are separated and collected for storage. The remaining cells are immediately returned to the blood circulation. The collected stem cells are stored in a cryo-preservation tank, and may be used for new regenerative therapies in the future.
ASFA is an organization of physicians, scientists, and allied health professionals whose mission is to lead the field of apheresis through patient and donor care, research, education, and advocacy. The vision of ASFA is to be the pre-eminent forum for the dissemination of evidenced-based knowledge, introduction of new information, and the exchange of new ideas in the field of apheresis medicine. The organization serves as the voice of investigators and practitioners to advance the development and delivery of programs and services in the field of apheresis medicine, benefiting patients, donors, and the general public.
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company also has licensed various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the ability to expand the Company's adult stem cell collection network, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010 and the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 17, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
For more information, please contact: NeoStem, Inc. Robin Smith, CEO Phone: +1-212-584-4174 Email: firstname.lastname@example.org Web: http://www.neostem.com CCG Investor Relations, Inc. Lei Huang, Account Manager Phone: +1-646-833-3417 Email: email@example.com Web: http://www.ccgirasia.com Crocker Coulson, President Phone: +1-646-213-1915 Email: firstname.lastname@example.org
SOURCE NeoStem, Inc.
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All